Infectious Disease Diagnostics Market Size, Share Report, Analysis, Trends, Growth 2030

Industry Prospective:

The global infectious disease diagnostics market was worth around USD 28152.7 million in 2021 and is estimated to grow to about USD 42013.25052 million by 2028, with a compound annual growth rate (CAGR) of approximately 6.9 percent over the forecast period. The report analyzes the digital remittance market’s drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the digital remittance market.

Infectious Disease Diagnostics Market: Overview

Infectious disease diagnostics is the procedure by which the causative agent of an infectious disease is identified and often characterized. It can be based solely on clinical presentation or more rigorous diagnostic tests, such as culturing of the infectious agent, microscopy, biochemical screens, and molecular methods. Diagnostic tests are crucial for diagnosing diseases and for the overall improvement of global health. Traditional methods were time-consuming and often produced inaccurate results. This led to the emergence of quick, accurate, and portable testing products in the market.

The growth of the infectious disease diagnosis market is mainly due to the increasing global prevalence of infectious diseases such as COVID-19, Ebola, Swine Flu, etc.; growing awareness for early detection using specific diagnostic tests; progress in funding for research on infectious disease diagnostics; and shift in focus from centralized laboratories to decentralized testing services.

COVID-19 Impact:

The COVID-19 pandemic had a positive impact on the infectious disease diagnostics market owing to the use of infectious disease diagnostic methods for COVID-19 testing. Lockdowns resulting from the COVID-19 pandemic caused people to delay undergoing health checkups, thus affecting the number of tests being performed and sales of reagents. However, a resurgence in testing numbers is seen as countries gradually ease restrictions on movement. With covid 19, people have become more conscious of infectious diseases, and responding to them has become a pressing medical issue globally. The COVID-19 pandemic has overall, stressed the healthcare systems in the world and amplified the need for the development of diagnostic instruments & diagnostic service centers. An increase in the number of COVID-19 cases coursed the demand for real-time polymerase chain reaction (RT-PCR) tests to detect COVID-19.

Request Free Sample

Infectious Disease Diagnostics Market: Growth Drivers

The global prevalence of infectious diseases and onset of COVID-19

The prevalence of infectious diseases in developed and developing regions positively influenced the growth of the infectious disease diagnostics market and is expected to be a major factor in its growth during the forecast period. The diagnosis and management of such diseases are responsible for the increasing number of prescriptions for infectious disease diagnostic tests. These factors, alongside the growing trend for preventive medicine, are expected to drive the demand for the infectious disease diagnostics market.

Infectious Disease Diagnostics Market: Restraints

Lack of accuracy of point of care diagnostic tests and Unfavorable reimbursement scenario

In underdeveloped and low-income regions, lack of training among clinicians and poor accessibility has led to decreased adoption of Infectious Disease Diagnostics test kits. Moreover, Inadequate reimbursement is a major factor restraining the growth of the infectious disease diagnostics market. A major challenge that most diagnostic companies face in commercializing their tests is getting health insurers to pay for them.

Infectious Disease Diagnostics Market: Segmentation

The global infectious disease diagnostics market is segregated based on product, type of testing, technology, disease type, and end-user.

By product, the global market is distinguished into Reagents, Kits, and Consumables, Instruments, and Software & Services. In 2020, the reagents, kits, and consumables segment accounted for the largest share of this market. The driving factor for the growth of this segment was the frequent purchase of these products due to their recurrent usage.

By technology, the global market is bifurcated into Immunodiagnostics, Clinical Microbiology, PCR, INAAT, DNA Sequencing & NGS, DNA Microarrays, and Other Technologies. The immunodiagnostics segment is projected to account for the largest share. This can be attributed to the increasing use of immunoassays in COVID-19 testing, POC infectious disease testing, the development of novel immunodiagnostic tests, and the rising trend of automation.

Report Scope:

Recent Developments

• In May 2021, Torus Biosystems revealed the USD 25 million series-A financing to advance infectious disease diagnostics across healthcare settings.
• In March 2020, Abbott Laboratories launched the ID NOW COVID-19 Test.

Regional Landscape

The infectious disease diagnostics market is dominated by North America in 2020 and is expected to dominate the market during the forecast period due to the rise in occurrence of infectious diseases, presence of key players, development of the healthcare sector, presence of national clinical laboratories, advancement in technology for diagnostic instruments in the region, and an increase in awareness among the population regarding the availability of treatment devices. However, Asia-Pacific is expected to register the highest CAGR from 2021 to 2028, owing to an increase in the prevalence of infectious diseases, a rise in demand for early diagnosis, development of healthcare infrastructure, technological advancement in diagnostic testing, and government efforts to improve the accessibility of diagnostic services to enhance the prevention by developing products or platforms required for the diagnosis of infectious diseases.

Competitive Landscape

Some of the main competitors dominating the global infectious disease diagnostics market include - Abbott Laboratories (US), F. Hoffmann-La Roche Ltd(Switzerland), bioMérieux SA (France), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Quidel Corporation(US), Hologic, Inc. (US), Siemens Healthineers AG (Germany), Becton, Dickinson and Company (US), PerkinElmer Inc. (US), QIAGEN (Netherlands), Grifols S.A. (Spain), DiaSorin S.p.A (Italy), Bio-Rad Laboratories, Inc. (US), Sysmex Corporation (Japan), Ortho Clinical Diagnostics (US), Luminex Corporation (US), Meridian Bioscience (US), Genetic Signatures (Australia), OraSure Technologies (US), Trinity Biotech Plc. (Ireland), Chembio Diagnostic Systems, Inc. (US), Seegene Inc. (South Korea), Co-Diagnostics, Inc. (US), ELITechGroup (France), Epitope Diagnostics, Inc. (US), Trivitron Healthcare (India), Meril Life Sciences Pvt. Ltd. (India), InBios International, Inc. (US), and ABACUS Diagnostica Oy (Finland).

Global infectious disease diagnostics market is segmented as follows:

By Product

• Reagents, Kits, and Consumables
• Instruments
• Software & Services

By Type of Testing

• Laboratory Testing
• POC Testing

By Technology

• Immunodiagnostics
• Clinical Microbiology
• PCR
• INAAT
• DNA Sequencing & NGS
• DNA Microarrays
• Other technologies

By Disease Type

• COVID-19
• HIV
• HAIs
• Hepatitis
• CT/NG
• HPV
• TB
• Influenza
• Other Infectious Diseases

By End-User

• Diagnostic Laboratories
• Hospitals & Clinics
• Academic Research Institutes
• Other End Users

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa